clinical trial · NCT04241549
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
OncoVerity, Inc.·phase1·completed·n = 6
Leukemia, Myeloid, AcuteCusatuzumabAzacitidine
brief summary
The purpose of this study is to determine the recommended Phase 2 dose and evaluate safety profile of cusatuzumab in combination with azacitidine in Japanese participants with treatment naïve acute myeloid leukemia (AML) who are not candidates for intensive treatment.
started
Mar 25, 2020
primary completion
Jul 19, 2021
completion
Jul 19, 2021
last updated
Aug 9, 2023
official title
A Phase 1 Study of Cusatuzumab Plus Azacitidine in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol